Literature DB >> 1397244

A randomized trial comparing the use of fresh and stored platelets in the treatment of bone marrow transplant recipients.

A Shanwell1, S Larsson, J Aschan, O Ringdén.   

Abstract

Patients undergoing allogeneic bone marrow transplantation (BMT) were randomized into two groups. One group (n = 21) received single donor platelet concentrates (PC) that were as fresh as possible, the other group (n = 18) received single donor PC stored for 2 to 5 days. Actual mean storage times for PC were 1.12 +/- 1.25 (mean +/- SD) and 2.67 +/- 1.30 d, respectively (p < 0.001). The total need for platelets during 60 d after BMT in patients receiving fresh PC was 22.1 +/- 17.8 x 10(9) platelet/liter blood volume/d, and for stored PC 29.2 +/- 19.2 x 10(9) platelets/liter blood volume/d (n.s.). A multiple regression analysis of the data showed no correlation between PC storage time and the PC requirement (p = 0.85). Posttransfusion corrected count increment (CCI) at 1 hour was 10.4 +/- 5.1 for PC stored 0-1 d, 10.3 +/- 7.0 for PC stored 2-3 d, and 11.4 +/- 9.2 for PC stored 4-5 d. The corresponding CCI, at 18 h were 6.5 +/- 4.4, 5.4 +/- 3.3 and 6.8 +/- 4.6. We conclude that there is no major difference between fresh and stored single donor PC.

Entities:  

Mesh:

Year:  1992        PMID: 1397244     DOI: 10.1111/j.1600-0609.1992.tb00035.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  5 in total

1.  Extended storage of buffy coat platelet concentrates in plasma or a platelet additive solution.

Authors:  Sherrill J Slichter; Doug Bolgiano; Jill Corson; Mary Kay Jones; Todd Christoffel; S Lawrence Bailey; Esther Pellham
Journal:  Transfusion       Date:  2014-03-28       Impact factor: 3.157

2.  What Laboratory Tests and Physiologic Triggers Should Guide the Decision to Administer a Platelet or Plasma Transfusion in Critically Ill Children and What Product Attributes Are Optimal to Guide Specific Product Selection? From the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding.

Authors:  Meghan Delaney; Oliver Karam; Lani Lieberman; Katherine Steffen; Jennifer A Muszynski; Ruchika Goel; Scot T Bateman; Robert I Parker; Marianne E Nellis; Kenneth E Remy
Journal:  Pediatr Crit Care Med       Date:  2022-01-01       Impact factor: 3.971

Review 3.  Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

Authors:  Lise J Estcourt; Simon J Stanworth; Carolyn Doree; Sally Hopewell; Marialena Trivella; Michael F Murphy
Journal:  Cochrane Database Syst Rev       Date:  2015-11-18

Review 4.  A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

Authors:  Gemma L Crighton; Lise J Estcourt; Erica M Wood; Marialena Trivella; Carolyn Doree; Simon Stanworth
Journal:  Cochrane Database Syst Rev       Date:  2015-09-30

Review 5.  Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

Authors:  Lise J Estcourt; Simon Stanworth; Carolyn Doree; Marialena Trivella; Sally Hopewell; Patricia Blanco; Michael F Murphy
Journal:  Cochrane Database Syst Rev       Date:  2015-10-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.